SITEMAP

• Products
  • Adacel®
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Cablivi®
    • HERCULES Study
      • Study Design
      • Hercules Summary
      • Platelet Count Normalization
      • aTTP-Related Events
      • Recurrences
      • Healthcare Resource Utilization
      • CABLIVI Safety Profile
    • aTTP Diagnosis and Treatment
      • Mechanism of Disease
      • CABLIVI Mechanism of Action
      • ISTH TTP Guidelines
    • Early Treatment Initiation
      • Real-World Evidence Studies
        • CNR-MAT Registry Study
        • Spanish
        • REACT-2020 and Aggregated Analysis
        • Italian
      • ISTH TTP Guidelines
      • CABLIVI-Specific Treatment Recommendation
      • Post-HERCULES
    • Delay in CABLIVI Start
      • Patient Outcomes
      • Active Disease
    • aTTP Sphere Digital Case Library
      • aTTP Sphere Digital Case Library - Kuwait
      • aTTP Sphere Digital Case Library - Qatar
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Atopic Dermatitis
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Plavix®
    • Tolerability
  • Praluent®
    • Praluent®
      • LDL-C Control
      • Tolerability
      • Patients at CV Risk
      • Starting Praluent®
    • It's Praluent of Course
      • Of Course
      • What is PRALUENT®?
      • Why choose PRALUENT®?
      • How to use PRALUENT®?
  • Sarclisa®
    • Sarclisa®
    • Sarclisa KD®
    • Sarclisa PD®
  • Soliqua®
    • For a Peaceful Ramadan
    • Soli-Simplify Study
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
  • Tavanic®
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
  • Xatral®
  • Zympass®
    • Zympass®
    • Zympass®
• Events
  • Cardiovascular
  • Diabetes
    • 2024
      • Dia-Tour: Navigating New Destinations in Diabetes Management
• Legal Notice
• Cookie Policy
• Privacy Policy
• Login
• Register
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
  • Cardiovascular
    • 2022
      • Act now for ACS patients by Prof. Mohamed Balgeith
      • Act Now for your ACS Patients
    • Are You Ready for 146? Achieving Optimal LDL-C Levels
    • Are You Ready for 556? Achieving Critical LDL-C Targets
    • Exploring the 556/146 Concept: Insights from Leading Experts
    • Understanding the 556/146 Concept: Insights from Leading Experts
    • 556/146 for Lipid Management after ACS
    • Why Praluent is the Optimal Choice for Post-ACS Patients?
    • How to Inject Praluent Once-Monthly 300 mg Pen?
    • How to Inject Praluent 75/150 mg Pen?
    • Act Now for your ACS Patients
    • Act now for ACS patients by Prof. Mohamed Balgeith
    • Act Now for your ACS Patients
    • Identify Your Patient
    • ESC/EAS Guidelines
    • Treat Early
    • ACS Europath Project
  • Diabetes
    • Tools and Resources
  • Rare Diseases
• Search
• Activate your Sanofi Account
• Error 404
• Oman Contact Details
• Events Calendar
• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
    • Cutting Edge Science
      • 2024
  • Anti-Infectives
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
            • Single Antiplatelet therapy: Insights on earlier use
            • Clopidogrel as the standard of care for elective PCI: Findings from the Alpheus
            • Understanding de-escalation in Antiplatelet therapy
            • Management of antithrombotic therapy in patients with AF undergoing PCI
          • 2023
            • No Rebound Effect Post Clopidogrel Withdrawal
            • Insights and impacts from the TALOS-AMI Trial
            • DAPT in Elderly with CAD Meta Analysis
            • Effectiveness and safety of Clopidogrel vs Aspirin
        • 2022
          • In hospital outcomes in young patients with AMI: Results from Gulf Coast
          • Adherence and persistence analysis in patients treated with DAPT
          • Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
          • Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
          • Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
        • 2023
          • Smart-choice trial_P2Y12 inhibitor monotherapy in complex PCI
          • Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS
          • Unguided de-escalation from Ticagrelor to Clopidogrel
          • Potent P2Y12 Inhibitors vs Clopidogrel in elderly ACS patients
          • P2Y12 inhibitor adherence trajectories in ACS
    • Dyslipidemia
    • Hypertension
    • Thrombosis
  • Chronic Obstructive Pulmonary Disease
  • Diabetes
    • Cutting Edge Science
      • Innovation
  • Eosinophilic Esophagitis
  • Multiple Myeloma
  • Multiple Sclerosis
  • Nasal Polyps
  • Neurological Disorders
    • Cutting Edge Science
  • Multiple Myeloma
    • Cutting Edge Science
      • 2022
  • Prurigo Nodularis
    • Cutting Edge Science
  • Rare Diseases
    • Cutting Edge Science
      • Innovation
  • Vaccines
    • Influenza
      • Cutting Edge Science
        • Innovation
    • Meningitis
    • Pertussis Polio
      • Cutting Edge Science
        • Innovation
    • RSV
      • Cutting Edge Science
        • 2024
          • Beyfortus®, an innovative immunization
          • Implementing Beyfortus successfully
          • Beyfortus in Action ECMMID
          • 2024 RSV International Congress ECMMID
          • Implementing Beyfortus successfully (ES)
          • Implementing Beyfortus successfully (FR)
          • Beyfortus in Action
          • Implementing Beyfortus successfully (US)
          • 2024 RSV International Congress - ESPID
          • Nirsevimab : Clinical Experience
          • Real World Evidence Impact of universal immunization with Nirsevimab